Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed

[1]  A. Tzioufas,et al.  COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review , 2021, Journal of Autoimmunity.

[2]  J. Hillert,et al.  Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry , 2021, Multiple sclerosis.

[3]  H. Vikram,et al.  COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review , 2021, Rheumatology International.

[4]  S. Falcão,et al.  Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab , 2021, BMJ Case Reports.

[5]  K. Winthrop,et al.  Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al , 2021, Annals of the Rheumatic Diseases.

[6]  E. Singas,et al.  Prolonged COVID-19 Disease in a Patient with Rheumatoid Arthritis on Rituximab Therapy , 2021, The Journal of infectious diseases.

[7]  A. Kenig,et al.  Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products , 2021, Clinical Immunology.

[8]  Julie M. Woessner,et al.  COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study , 2021, The Lancet Rheumatology.

[9]  Y. Ruch,et al.  Protracted SARS‐CoV‐2 pneumonia with rituximab treatment: About two cases , 2021, Journal of medical virology.

[10]  K. Winthrop,et al.  Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab , 2021, Annals of the Rheumatic Diseases.

[11]  M. Gianfrancesco,et al.  Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al , 2021, Annals of the Rheumatic Diseases.

[12]  L. Quartuccio,et al.  Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis , 2021, Rheumatology.

[13]  L. Trupin,et al.  Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2021, Annals of the Rheumatic Diseases.

[14]  M. Malinis,et al.  Prolonged incubation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient on rituximab therapy , 2020, Infection Control & Hospital Epidemiology.

[15]  M. Riachy,et al.  COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm. , 2020, European journal of case reports in internal medicine.

[16]  M. Benucci,et al.  Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al , 2020, Annals of the Rheumatic Diseases.

[17]  M. Ebert,et al.  Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab , 2020, Seminars in Arthritis and Rheumatism.

[18]  M. Matucci-Cerinic,et al.  Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab , 2020, Annals of the Rheumatic Diseases.

[19]  A. Skapenko,et al.  Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab , 2020, Annals of the Rheumatic Diseases.

[20]  P. Taourel,et al.  Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia , 2020, Annals of the Rheumatic Diseases.

[21]  S. Bombardieri,et al.  The diagnosis and classification of mixed connective tissue disease. , 2014, Journal of autoimmunity.